Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma.

PubWeight™: 2.44‹?› | Rank: Top 2%

🔗 View Article (PMID 7707437)

Published in J Natl Cancer Inst on April 05, 1995

Authors

C A Boocock1, D S Charnock-Jones, A M Sharkey, J McLaren, P J Barker, K A Wright, P R Twentyman, S K Smith

Author Affiliations

1: Department of Obstetrics and Gynaecology, University of Cambridge, Rosie Maternity Hospital, England.

Associated clinical trials:

Neoadjuvant Bevacizumab and Carboplatin Followed by Concurrent Bevacizumab, Carboplatin and Radiotherapy in the Primary Treatment of Cervix Cancer | NCT00600210

Articles citing this

Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer (1998) 3.93

Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1. PLoS Med (2007) 2.37

Molecular determinants of ovarian cancer plasticity. Am J Pathol (2001) 2.32

Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes. PLoS One (2014) 1.99

Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol (1998) 1.90

Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. Br J Cancer (1996) 1.84

Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br J Cancer (1997) 1.72

Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma. Am J Pathol (2002) 1.70

Vascular endothelial growth factor is produced by peritoneal fluid macrophages in endometriosis and is regulated by ovarian steroids. J Clin Invest (1996) 1.63

Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer. Br J Cancer (1998) 1.58

Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Br J Cancer (2000) 1.51

Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas. Am J Pathol (2001) 1.49

Angiogenesis in cancer. Vasc Health Risk Manag (2006) 1.49

Role of endothelin-1 in neovascularization of ovarian carcinoma. Am J Pathol (2000) 1.44

Concentration of vascular endothelial growth factor in the tumour tissue as a prognostic factor of soft tissue sarcomas. Br J Cancer (2001) 1.41

Importance of vascular phenotype by basic fibroblast growth factor, and influence of the angiogenic factors basic fibroblast growth factor/fibroblast growth factor receptor-1 and ephrin-A1/EphA2 on melanoma progression. Am J Pathol (2002) 1.31

Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer. Cancer Metastasis Rev (2012) 1.31

GADD45 proteins: central players in tumorigenesis. Curr Mol Med (2012) 1.26

Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. J Clin Oncol (2010) 1.26

Vascular growth factors and receptors in capillary hemangioblastomas and hemangiopericytomas. Am J Pathol (1996) 1.25

Angiogenesis in epithelian ovarian cancer. Mol Pathol (2002) 1.21

ETS-1 protein regulates vascular endothelial growth factor-induced matrix metalloproteinase-9 and matrix metalloproteinase-13 expression in human ovarian carcinoma cell line SKOV-3. J Biol Chem (2012) 1.19

Intramolecularly folded G-quadruplex and i-motif structures in the proximal promoter of the vascular endothelial growth factor gene. Nucleic Acids Res (2008) 1.16

Differential expression of vascular endothelial growth factor mRNA vs protein isoform expression in human breast cancer and relationship to eIF-4E. Br J Cancer (1998) 1.16

The expression of vascular endothelial growth factor C and its receptors in non-small cell lung cancer. Br J Cancer (2001) 1.16

Src homology 2 (SH2) domain containing protein tyrosine phosphatase-1 (SHP-1) dephosphorylates VEGF Receptor-2 and attenuates endothelial DNA synthesis, but not migration*. J Mol Signal (2008) 1.11

Novel function for vascular endothelial growth factor receptor-1 on epidermal keratinocytes. Am J Pathol (2005) 1.09

Novel soluble Flt-1 isoforms in plasma and cultured placental explants from normotensive pregnant and preeclamptic women. Placenta (2008) 1.07

Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix. Br J Cancer (2000) 1.07

Loss of ovarian function promotes angiogenesis in human ovarian carcinoma. Proc Natl Acad Sci U S A (1997) 1.06

Production of VEGF and expression of the VEGF receptors Flt-1 and KDR in primary cultures of epithelial and stromal cells derived from breast tumours. Br J Cancer (1999) 1.06

VEGF significance in peritoneal recurrence from gastric cancer. Gastric Cancer (2005) 1.06

Immunolocalisation of the VEGF receptors FLT-1, KDR, and FLT-4 in diabetic retinopathy. Br J Ophthalmol (1999) 1.05

Diverse mechanisms for activation of Wnt signalling in the ovarian tumour microenvironment. Biochem J (2011) 1.05

Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib. Clin Cancer Res (2009) 1.03

Angiogenesis is associated with vascular endothelial growth factor expression in cervical intraepithelial neoplasia. Br J Cancer (1997) 1.01

Prognostic value of vascular endothelial growth factor (VEGF) in head and neck squamous cell carcinomas. Br J Cancer (2000) 1.00

Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer. Clin Cancer Res (2010) 0.99

Correlation of vascular endothelial growth factor expression with fibroblast growth factor-8 expression and clinico-pathologic parameters in human prostate cancer. Br J Cancer (2001) 0.99

Clinicopathological significance of hypoxia-inducible factor-1 alpha (HIF-1α) expression in gastric cancer. Int J Clin Oncol (2012) 0.97

Role of vascular endothelial growth factor inhibitors in the treatment of gynecologic malignancies. J Gynecol Oncol (2010) 0.94

What is the role of vascular endothelial growth factor-related molecules in tumor angiogenesis? Am J Pathol (1998) 0.93

Targeted therapies in epithelial ovarian cancer: Molecular mechanisms of action. World J Biol Chem (2010) 0.91

Vascular endothelial growth factor receptor-2-mediated mitogenesis is negatively regulated by vascular endothelial growth factor receptor-1 in tumor epithelial cells. Am J Pathol (2001) 0.91

Prognostic significance of vascular endothelial growth factor serum determination in women with ovarian cancer. ISRN Obstet Gynecol (2012) 0.90

Vascular endothelial growth factor expression in ovarian serous carcinomas and its effect on tumor proliferation. South Asian J Cancer (2013) 0.89

Vascular endothelial growth factor-165 overexpression stimulates angiogenesis and induces cyst formation and macrophage infiltration in human ovarian cancer xenografts. Am J Pathol (2002) 0.88

Tumor cell expression of vascular endothelial growth factor receptor 2 is an adverse prognostic factor in patients with squamous cell carcinoma of the lung. PLoS One (2013) 0.88

Vascular endothelial growth factor expression is independent of hypoxia in human malignant glioma spheroids and tumours. Br J Cancer (2000) 0.87

Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models. Br J Cancer (2012) 0.86

Quercetin-4'-O-β-D-glucopyranoside (QODG) inhibits angiogenesis by suppressing VEGFR2-mediated signaling in zebrafish and endothelial cells. PLoS One (2012) 0.86

Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with suspected ovarian cancer. Br J Cancer (1998) 0.85

Clinical implications of expression of vascular endothelial growth factor in metastatic lesions of ovarian cancers. Br J Cancer (2001) 0.85

High efficacy of CpG-ODN, cetuximab and cisplatin combination for very advanced ovarian xenograft tumors. J Transl Med (2013) 0.85

Soluble flt-1 and the angiopoietins in the development and regulation of placental vasculature. J Anat (2002) 0.84

Combinatorial effect of non-steroidal anti-inflammatory drugs and NF-κB inhibitors in ovarian cancer therapy. PLoS One (2011) 0.84

Visualization of tumor angiogenesis using MR imaging contrast agent Gd-DTPA-anti-VEGF receptor 2 antibody conjugate in a mouse tumor model. Korean J Radiol (2010) 0.84

Evaluation of serum vascular endothelial growth factor (VEGF) and microvessel density (MVD) as prognostic indicators in carcinoma breast. J Cancer Res Clin Oncol (2008) 0.84

Purinergic mechanisms in breast cancer support intravasation, extravasation and angiogenesis. Cancer Lett (2010) 0.84

Vascular endothelial growth factor expression and inhibition in uveal melanoma cell lines. Ecancermedicalscience (2013) 0.82

DNA methylation regulates expression of VEGF-R2 (KDR) and VEGF-R3 (FLT4). BMC Cancer (2012) 0.82

Immunization with synthetic VEGF peptides in ovarian cancer. Gynecol Oncol (2010) 0.81

Expression of the VEGF and angiopoietin genes in endometrial atypical hyperplasia and endometrial cancer. Br J Cancer (2003) 0.79

Imaging-guided delivery of RNAi for anticancer treatment. Adv Drug Deliv Rev (2016) 0.79

Double suicide genes driven by kinase domain insert containing receptor promoter selectively kill human lung cancer cells. Genet Vaccines Ther (2011) 0.79

Novel compounds with antiangiogenic and antiproliferative potency for growth control of testicular germ cell tumours. Br J Cancer (2010) 0.78

Evaluation of potentially predictive markers for anti-angiogenic therapy with sunitinib in recurrent ovarian cancer patients. Transl Oncol (2013) 0.78

Vascular endothelial growth factor expression correlates with serum CA125 and represents a useful tool in prediction of refractoriness to platinum-based chemotherapy and ascites formation in epithelial ovarian cancer. Oncotarget (2015) 0.76

Evidence of a genetic link between endometriosis and ovarian cancer. Fertil Steril (2015) 0.76

Identification of common mechanisms between endometriosis and ovarian cancer. J Assist Reprod Genet (2011) 0.76

Effects of vascular endothelial growth factor expression on pathological characteristics and prognosis of osteosarcoma. Clin Exp Med (2015) 0.75

Anti-tumour activity of tivozanib, a pan-inhibitor of VEGF receptors, in therapy-resistant ovarian carcinoma cells. Sci Rep (2017) 0.75

Vascular endothelial growth factor: environmental controls and effects in angiogenesis. Br J Cancer Suppl (1996) 0.75

Evaluation of the angiogenesis inhibitor KR-31831 in SKOV-3 tumor-bearing mice using (64)Cu-DOTA-VEGF(121) and microPET. Nucl Med Biol (2012) 0.75

Science and technology of the emerging nanomedicines in cancer therapy: A primer for physicians and pharmacists. SAGE Open Med (2013) 0.75

Ultrasound Molecular Imaging of Angiogenesis Using Vascular Endothelial Growth Factor-Conjugated Microbubbles. Mol Pharm (2017) 0.75

Articles by these authors

Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med (2001) 6.73

A new mouse tumor model system (RIF-1) for comparison of end-point studies. J Natl Cancer Inst (1980) 3.75

Stress signaling in plants: a mitogen-activated protein kinase pathway is activated by cold and drought. Proc Natl Acad Sci U S A (1996) 2.80

A novel site-targeted ultrasonic contrast agent with broad biomedical application. Circulation (1996) 2.72

Clonal dominance among T-lymphocyte infiltrates in arthritis. Proc Natl Acad Sci U S A (1988) 2.36

Aspects of human fetoplacental vasculogenesis and angiogenesis. III. Changes in complicated pregnancies. Placenta (2004) 2.29

Conserved reiterated domains in Clostridium thermocellum endoglucanases are not essential for catalytic activity. Gene (1988) 2.25

A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. Biol Reprod (1998) 2.12

Studies of "potentially lethal damage" in EMT6 mouse tumour cells treated with bleomycin either in vitro or in vivo. Br J Cancer (1975) 2.02

Randomised controlled trial of educational package on management of menorrhagia in primary care: the Anglia menorrhagia education study. BMJ (1999) 1.96

The sensitivity to bleomycin of a solid mouse tumour at different stages of growth. Br J Cancer (1974) 1.88

An inducible 50-kilodalton NF kappa B-like protein and a constitutive protein both bind the acute-phase response element of the angiotensinogen gene. Mol Cell Biol (1990) 1.81

Treatment of experimental cryptococcal meningitis and disseminated candidiasis with SCH39304. Antimicrob Agents Chemother (1989) 1.78

Aspects of human fetoplacental vasculogenesis and angiogenesis. II. Changes during normal pregnancy. Placenta (2004) 1.74

A systematic review and meta-analysis of family history and risk of ovarian cancer. Br J Obstet Gynaecol (1998) 1.70

Alternative splicing of vascular endothelial growth factor (VEGF)-R1 (FLT-1) pre-mRNA is important for the regulation of VEGF activity. Mol Endocrinol (1999) 1.70

Placental endoplasmic reticulum stress and oxidative stress in the pathophysiology of unexplained intrauterine growth restriction and early onset preeclampsia. Placenta (2008) 1.67

Derivation and preliminary characterisation of adriamycin resistant lines of human lung cancer cells. Br J Cancer (1986) 1.66

Properties and partial protein sequence of plant annexins. Plant Physiol (1992) 1.65

Vascular endothelial growth factor is produced by peritoneal fluid macrophages in endometriosis and is regulated by ovarian steroids. J Clin Invest (1996) 1.63

VEGF mRNA levels in placentae from pregnancies complicated by pre-eclampsia. Br J Obstet Gynaecol (1996) 1.63

9-Alkyl, morpholinyl anthracyclines in the circumvention of multidrug resistance. Eur J Cancer (1990) 1.59

Localization of VEGF and expression of its receptors flt and KDR in human placenta throughout pregnancy. Hum Reprod (1996) 1.58

Is genetic code redundancy related to retention of structural information in both DNA strands? Trends Biochem Sci (1990) 1.57

Nimesulide, a COX-2 inhibitor, does not reduce lesion size or number in a nude mouse model of endometriosis. Hum Reprod (2004) 1.55

Establishment and characterisation of cell lines from patients with lung cancer (predominantly small cell carcinoma). Br J Cancer (1985) 1.52

The effect of time between X-irradiation and chemotherapy on the growth of three solid mouse tumors--I. Adriamycin. Int J Radiat Oncol Biol Phys (1979) 1.49

Normal human keratocyte density and corneal thickness measurement by using confocal microscopy in vivo. Invest Ophthalmol Vis Sci (2001) 1.47

Evidence for the expression of HLAA-C class I mRNA and protein by human first trimester trophoblast. J Immunol (1996) 1.46

Identification and localization of alternately spliced mRNAs for vascular endothelial growth factor in human uterus and estrogen regulation in endometrial carcinoma cell lines. Biol Reprod (1993) 1.45

Sensitive detection of abnormal aortic architecture in Marfan syndrome with high-frequency ultrasonic tissue characterization. Circulation (1995) 1.42

Microbial degradation of 4-carboxy-1-methyl-pyridinium chloride, a photolytic product of paraquat. Biochem J (1970) 1.41

Binding of gelatinases A and B to type-I collagen and other matrix components. Biochem J (1995) 1.41

Cyclosporin A and its analogues as modifiers of adriamycin and vincristine resistance in a multi-drug resistant human lung cancer cell line. Br J Cancer (1987) 1.40

A 190-kilodalton protein overexpressed in non-P-glycoprotein-containing multidrug-resistant cells and its relationship to the MRP gene. J Natl Cancer Inst (1994) 1.39

A mammalian epididymal protein with remarkable sequence similarity to snake venom haemorrhagic peptides. Biochem J (1992) 1.38

Gynaecology--medical or surgical? BMJ (1996) 1.38

Modification of tumour and host response to cyclophosphamide by misonidazole and by WR 2721. Br J Cancer (1981) 1.38

Response to chemotherapy of EMT6 spheroids as measured by growth delay and cell survival. Br J Cancer (1980) 1.38

Sensitivity to cytotoxic agents of the EMT6 tumour in vivo: tumour volume versus in vitro plating. 1. Cyclophosphamide. Br J Cancer (1977) 1.36

Tumor biology of infiltrating lobular carcinoma. Implications for management. Ann Surg (1995) 1.35

Prostaglandin synthesis in the endometrium of women with ovular dysfunctional uterine bleeding. Br J Obstet Gynaecol (1981) 1.34

Examination by laser scanning confocal fluorescence imaging microscopy of the subcellular localisation of anthracyclines in parent and multidrug resistant cell lines. Br J Cancer (1993) 1.34

Regulation of vascular growth and function in the human placenta. Reproduction (2009) 1.33

Trichinella spiralis: an intracellular parasite in the intestinal phase. J Parasitol (1979) 1.33

Angiogenic growth factor messenger ribonucleic acids in uterine natural killer cells. J Clin Endocrinol Metab (2001) 1.32

Regulation by glutathione of drug transport in multidrug-resistant human lung tumour cell lines overexpressing multidrug resistance-associated protein. Br J Cancer (1995) 1.32

Development of cowpea mosaic virus as a high-yielding system for the presentation of foreign peptides. Virology (1994) 1.32

Maternal plasma levels of vascular endothelial growth factor in normotensive pregnancies and in pregnancies complicated by pre-eclampsia. Eur J Clin Invest (1996) 1.31

Predictive chemosensitivity testing. Br J Cancer (1985) 1.30

The response to cytotoxic drugs of EMT6 cells treated either as intact or disaggregated spheroids. Br J Cancer (1985) 1.28

Treatment of experimental disseminated candidiasis with cilofungin. Antimicrob Agents Chemother (1989) 1.26

Properties of large-conductance K+ channels in human myometrium during pregnancy and labour. Proc Biol Sci (1993) 1.26

New protocols for DNA sequencing with dye terminators. DNA Seq (1992) 1.25

Management of menorrhagia: an audit of practices in the Anglia menorrhagia education study. BMJ (2001) 1.23

Production of the hexitol D-mannitol by Cryptococcus neoformans in vitro and in rabbits with experimental meningitis. Infect Immun (1990) 1.23

Leukaemia inhibitory factor mRNA concentration peaks in human endometrium at the time of implantation and the blastocyst contains mRNA for the receptor at this time. J Reprod Fertil (1994) 1.22

Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. Br J Obstet Gynaecol (1995) 1.22

The cellodextrinase from Pseudomonas fluorescens subsp. cellulosa consists of multiple functional domains. Biochem J (1991) 1.22

Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database Syst Rev (2000) 1.21

Amphotericin B lipid complex in the treatment of experimental cryptococcal meningitis and disseminated candidosis. J Antimicrob Chemother (1994) 1.21

Vascular endothelial growth factor receptor localization and activation in human trophoblast and choriocarcinoma cells. Biol Reprod (1994) 1.20

Some characteristics of a population of mentally retarded young adults in a British city. A basis for estimating some service needs. J Ment Defic Res (1979) 1.20

Transcatheter coil embolisation of a pulmonary arteriovenous malformation in a neonate. Br Heart J (1994) 1.19

Chemosensitisation and drug accumulation effects of cyclosporin A, PSC-833 and verapamil in human MDR large cell lung cancer cells expressing a 190k membrane protein distinct from P-glycoprotein. Eur J Cancer (1993) 1.18

Expression of mRNA for vascular endothelial growth factor in human placenta. J Reprod Fertil (1993) 1.18

Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma. Br J Cancer (2003) 1.18

Muscle growth in response to mechanical stimuli. Am J Physiol (1995) 1.18

Evaluation of the Pneumoslide latex agglutination test for identification of Streptococcus pneumoniae. J Clin Microbiol (1984) 1.17

Use of bacterial neutral protease for disaggregation of mouse tumours and multicellular tumor spheroids. Cancer Lett (1980) 1.16

Nov gene encodes adhesion factor for vascular smooth muscle cells and is dynamically regulated in response to vascular injury. Arterioscler Thromb Vasc Biol (2000) 1.16

The MTT assay underestimates the growth inhibitory effects of interferons. Br J Cancer (1989) 1.16

Timing of assays: an important consideration in the determination of clonogenic cell survival both in vitro and in vivo. Int J Radiat Oncol Biol Phys (1979) 1.15

Drug resistance in human lung cancer cell lines: cross-resistance studies and effects of the calcium transport blocker, verapamil. Int J Radiat Oncol Biol Phys (1986) 1.15

Human early placental development: potential roles of the endometrial glands. Placenta (2007) 1.14

Pyridine nucleotide metabolism in Escherichia coli. 3. Biosynthesis from alternative precursors in vivo. J Biol Chem (1973) 1.14

Changes in cell proliferation kinetics occurring during the life history of monolayer cultures of a mouse tumour cell line. Cell Tissue Kinet (1975) 1.14

The sensitivity of cells in exponential and stationary phases of growth to bleomycin and to 1,3-bis(2-chloroethyl)-1-nitrosourea. Br J Cancer (1973) 1.13

Vascular endothelial growth factor (VEGF) concentrations are elevated in peritoneal fluid of women with endometriosis. Hum Reprod (1996) 1.12

The sensitivity to cytotoxic agents of the EMT6 tumor in vivo. Comparative response of lung nodules in rapid expotential growth and of the solid flank tumour. Br J Cancer (1976) 1.12